Daniel M Schmid
Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction
Müller J, von Schulthess G, Kaufmann P, Kranzbuehler H, John H, Zilli T, Müller A, Omlin A, Schmid D, Sulser T, Kroeze S, Guckenberger M, Eberli D, Kedzia S, Garcia Schüler H, Muehlematter U, Ferraro D, Burger I. Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. Eur J Nucl Med Mol Imaging 2018
Nov 28, 2018Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction
Nov 28, 2018Eur J Nucl Med Mol Imaging 2018
Müller Julian, von Schulthess Gustav K, Kaufmann Philipp A, Kranzbuehler Helmut, John Hubert, Zilli Thomas, Müller Alexander, Omlin Aurelius, Schmid Daniel M, Sulser Tullio, Kroeze Stephanie G C, Guckenberger Matthias, Eberli Daniel, Kedzia Sarah, Garcia Schüler Helena I, Muehlematter Urs J, Ferraro Daniela A, Burger Irene A
Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland
Kessler T, Zrehen S, Schurch B, Schmid D, Roche B, Iselin C, Bersch U, Al-Khodairy A, Engeler D, Meyer S, Buchser E, Burkhard F. Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland. European urology 2007; 51:1357-63.
May 1, 2007Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland
May 1, 2007European urology 2007; 51:1357-63
Kessler Thomas M, Zrehen Stephane, Schurch Brigitte, Schmid Daniel M, Roche Bruno, Iselin Christophe E, Bersch Ulf, Al-Khodairy Abdul-Wahab, Engeler Daniel, Meyer Sylvain, Buchser Eric, Burkhard Fiona C